Want to see HK:0239 full AI Analyst Report?
0239 Stock Chart & Stats
HK$2.38
-HK$0.03(-1.22%)
At close: 4:00 PM EST
HK$2.38
-HK$0.03(-1.22%)
Day’s Range― - ―
52-Week RangeHK$2.24 - HK$2.55
Previous CloseN/A
Volume52.50K
Average Volume (3M)22.62K
Market Cap
HK$738.59M
Enterprise ValueHK$400.92
Total Cash (Recent Filing)HK$344.54M
Total Debt (Recent Filing)HK$6.87M
Price to Earnings (P/E)7.9
Beta-0.14
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield7.81%
Share Statistics
EPS (TTM)0.30
Shares Outstanding311,640,000
10 Day Avg. Volume26,750
30 Day Avg. Volume22,616
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)1.02
Price to Sales (P/S)3.45
P/FCF Ratio6.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a conservative balance sheet provide durable financial flexibility: the company can fund capex, dividends, or weather demand shocks without relying on external debt, lowering solvency risk and supporting long-term strategic optionality.
Strong Cash GenerationRobust operating and free cash flow over recent years—including a 2025 step-up—indicates durable cash conversion from earnings. This supports sustainable shareholder distributions, reinvestment in the brand and manufacturing, and reduces reliance on external financing for growth.
High Profitability MarginsVery high recent margins reflect strong unit economics and pricing power for core products. Sustained profitability enables reinvestment in marketing and distribution, supports cash returns to shareholders, and cushions the business against moderate revenue weakness.
Bears Say
Revenue VolatilityRepeated top-line declines and mixed revenue trends reduce visibility on growth sustainability. Persistent or recurring revenue weakness can pressure margins, constrain long-term reinvestment, and make forecasting cashflows and dividends less reliable for investors.
Earnings And Returns VolatilityHistoric swings in returns and past loss-making periods indicate sensitivity to cyclical or operational shocks. Such volatility undermines confidence in earnings persistence, complicates capital allocation decisions, and increases the risk that payouts or investments will be cut during downturns.
Concentrated Product/Market FocusHeavy reliance on a single branded OTC product line and related consumer health channels limits diversification. That concentration raises exposure to shifting consumer preferences, regulatory changes, or competitive entry, constraining scalable growth levers over multiple years.
Pak Fah Yeow International Limited News
0239 FAQ
What was Pak Fah Yeow International Limited’s price range in the past 12 months?
Pak Fah Yeow International Limited lowest stock price was HK$2.24 and its highest was HK$2.55 in the past 12 months.
What is Pak Fah Yeow International Limited’s market cap?
Pak Fah Yeow International Limited’s market cap is HK$738.59M.
When is Pak Fah Yeow International Limited’s upcoming earnings report date?
Pak Fah Yeow International Limited’s upcoming earnings report date is Aug 20, 2026 which is in 6 days.
How were Pak Fah Yeow International Limited’s earnings last quarter?
Pak Fah Yeow International Limited released its earnings results on Mar 30, 2026. The company reported HK$0.166 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Pak Fah Yeow International Limited overvalued?
According to Wall Street analysts Pak Fah Yeow International Limited’s price is currently Overvalued.
Does Pak Fah Yeow International Limited pay dividends?
Pak Fah Yeow International Limited pays a Notavailable dividend of HK$0.11 which represents an annual dividend yield of 7.81%. See more information on Pak Fah Yeow International Limited dividends here
What is Pak Fah Yeow International Limited’s EPS estimate?
Pak Fah Yeow International Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pak Fah Yeow International Limited have?
Pak Fah Yeow International Limited has 311,640,000 shares outstanding.
What happened to Pak Fah Yeow International Limited’s price movement after its last earnings report?
Pak Fah Yeow International Limited reported an EPS of HK$0.166 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.231%.
Which hedge fund is a major shareholder of Pak Fah Yeow International Limited?
Currently, no hedge funds are holding shares in HK:0239
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pak Fah Yeow International Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.39%
12-Months-Change
Fundamentals
Return on Equity
7.81%
Trailing 12-Months
Asset Growth
-1.78%
Trailing 12-Months
Company Description
Pak Fah Yeow International Limited
Pak Fah Yeow International Limited, operating with its subsidiaries, specializes in the production, promotion, and distribution of healthcare goods under the Hoe Hin brand. Its market reach spans the People's Republic of China, Hong Kong, Macau, Southeast Asia, North America, the United Kingdom, and other international territories. The company's operations are categorized into three distinct divisions: Healthcare, Property Investments, and Treasury Investments. Among its key offerings are medicated oils, such as white flower embrocation, along with various ointments and solutions for strain relief, including the floral-scented Fúzai 239 white flower embrocation. Beyond its primary healthcare focus, the firm also commits capital to diverse real estate assets, encompassing commercial, industrial, residential, and car park properties, and additionally provides advertising agency services. This enterprise, established in 1927, maintains its corporate headquarters in Wan Chai, Hong Kong.
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
JBM (Healthcare) Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Jacobson Pharma Corporation Limited
―